As China's first and currently only approved subcutaneous injection formulation for the treatment of EGFR-mutant advanced non-small cell lung cancer, Rybrevant FASPRO reduces the administration time from several hours with traditional intravenous infusion to just minutes, and significantly reduces the risk of infusion-related adverse reactions.
Johnson & Johnson today announced the official launch of Rybrevant FASPRO (amivantamab injection, subcutaneous) in China, in combination with LECLIZE (lazertinib mesylate tablets) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R substitution mutation.
Rybrevant FASPRO is the first and currently only subcutaneous injection formulation approved in China for the treatment of patients with EGFR-mutant advanced NSCLC. Combined with lazertinib, it demonstrates significant ease of administration in first-line combination therapy, reducing administration time from several hours to just minutes.
In terms of safety, compared with the intravenous formulation, Rybrevant FASPRO showed a significantly lower incidence of infusion-related adverse events (13% vs. 66%). In patients receiving Rybrevant FASPRO in combination with lazertinib plus prophylactic anticoagulation (n=164), the observed incidence of venous thromboembolism was 7%, similar to the baseline risk in advanced NSCLC patients.
The 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines for NSCLC have included the first-line combination of Rybrevant FASPRO plus lazertinib as a recommended regimen for EGFR-mutant advanced NSCLC.

Source: https://mp.weixin.qq.com/s?__biz=MzAwNzI1MjYwNQ==&mid=2653242396&idx=1&sn=c5249aa7831843e8b07230670c02e0fa